Literature DB >> 36028293

Complement Is Required for Microbe-Driven Induction of Th17 and Periodontitis.

Hui Wang1, Hidetaka Ideguchi1,2, Tetsuhiro Kajikawa1,3, Dimitrios C Mastellos4, John D Lambris5, George Hajishengallis6.   

Abstract

In both mice and humans, complement and Th17 cells have been implicated in periodontitis, an oral microbiota-driven inflammatory disease associated with systemic disorders. A recent clinical trial showed that a complement C3 inhibitor (AMY-101) causes sustainable resolution of periodontal inflammation, the main effector of tissue destruction in this oral disease. Although both complement and Th17 are required for periodontitis, it is uncertain how these immune components cooperate in disease development. In this study, we dissected the complement-Th17 relationship in the setting of ligature-induced periodontitis (LIP), a model that previously established that microbial dysbiosis drives Th17 cell expansion and periodontal bone loss. Complement was readily activated in the periodontal tissue of LIP-subjected mice but not when the mice were placed on broad-spectrum antibiotics. Microbiota-induced complement activation generated critical cytokines, IL-6 and IL-23, which are required for Th17 cell expansion. These cytokines as well as Th17 accumulation and IL-17 expression were significantly suppressed in LIP-subjected C3-deficient mice relative to wild-type controls. As IL-23 has been extensively studied in periodontitis, we focused on IL-6 and showed that LIP-induced IL-17 and bone loss required intact IL-6 receptor signaling in the periodontium. LIP-induced IL-6 was predominantly produced by gingival epithelial cells that upregulated C3a receptor upon LIP challenge. Experiments in human gingival epithelial cells showed that C3a upregulated IL-6 production in cooperation with microbial stimuli that upregulated C3a receptor expression in ERK1/2- and JNK-dependent manner. In conclusion, complement links the periodontal microbiota challenge to Th17 cell accumulation and thus integrates complement- and Th17-driven immunopathology in periodontitis.
Copyright © 2022 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36028293      PMCID: PMC9530003          DOI: 10.4049/jimmunol.2200338

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.426


  62 in total

Review 1.  Complement: a key system for immune surveillance and homeostasis.

Authors:  Daniel Ricklin; George Hajishengallis; Kun Yang; John D Lambris
Journal:  Nat Immunol       Date:  2010-08-19       Impact factor: 25.606

2.  DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates.

Authors:  Jieun Shin; Tomoki Maekawa; Toshiharu Abe; Evlambia Hajishengallis; Kavita Hosur; Kalyani Pyaram; Ioannis Mitroulis; Triantafyllos Chavakis; George Hajishengallis
Journal:  Sci Transl Med       Date:  2015-09-30       Impact factor: 17.956

Review 3.  Periodontal diseases.

Authors:  Denis F Kinane; Panagiota G Stathopoulou; Panos N Papapanou
Journal:  Nat Rev Dis Primers       Date:  2017-06-22       Impact factor: 52.329

Review 4.  Oral diseases: a global public health challenge.

Authors:  Marco A Peres; Lorna M D Macpherson; Robert J Weyant; Blánaid Daly; Renato Venturelli; Manu R Mathur; Stefan Listl; Roger Keller Celeste; Carol C Guarnizo-Herreño; Cristin Kearns; Habib Benzian; Paul Allison; Richard G Watt
Journal:  Lancet       Date:  2019-07-20       Impact factor: 79.321

5.  Bacterial fimbriae and their peptides activate human gingival epithelial cells through Toll-like receptor 2.

Authors:  Y Asai; Y Ohyama; K Gen; T Ogawa
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

6.  C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion.

Authors:  Joshua M Thurman; Amanda M Lenderink; Pamela A Royer; Kathrin E Coleman; Jian Zhou; John D Lambris; Raphael A Nemenoff; Richard J Quigg; V Michael Holers
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

7.  Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.

Authors:  Hatice Hasturk; George Hajishengallis; John D Lambris; Dimitrios C Mastellos; Despina Yancopoulou
Journal:  J Clin Invest       Date:  2021-12-01       Impact factor: 19.456

8.  Complement drives Th17 cell differentiation and triggers autoimmune arthritis.

Authors:  Motomu Hashimoto; Keiji Hirota; Hiroyuki Yoshitomi; Shinji Maeda; Shin Teradaira; Shuji Akizuki; Paz Prieto-Martin; Takashi Nomura; Noriko Sakaguchi; Jörg Köhl; Birgitta Heyman; Minoru Takahashi; Teizo Fujita; Tsuneyo Mimori; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2010-05-10       Impact factor: 14.307

9.  Induction of bone loss by pathobiont-mediated Nod1 signaling in the oral cavity.

Authors:  Yizu Jiao; Youssef Darzi; Kazuki Tawaratsumida; Julie T Marchesan; Mizuho Hasegawa; Henry Moon; Grace Y Chen; Gabriel Núñez; William V Giannobile; Jeroen Raes; Naohiro Inohara
Journal:  Cell Host Microbe       Date:  2013-05-15       Impact factor: 21.023

10.  Activation of Notch-1 in oral epithelial cells by P. gingivalis triggers the expression of the antimicrobial protein PLA2-IIA.

Authors:  Ahmad Al-Attar; Yelena Alimova; Sreenatha Kirakodu; Anastasia Kozal; Michael John Novak; Arnold J Stromberg; Luis Orraca; Janis Gonzalez-Martinez; Melween Martinez; Jeffrey L Ebersole; Octavio A Gonzalez
Journal:  Mucosal Immunol       Date:  2018-03-07       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.